Overview of Glucagon Like Peptide 1 Receptor Agonists And Heart Failure

With worsening epidemiological trends for both the incidence and prevalence of type 2 diabetes mellitus (T2DM) and heart failure (HF) worldwide, it is critical to implement optimal prevention and treatment strategies for patients with these comorbidities, either alone or concomitantly. Several guidelines and consensus statements have recommended glucagon-like peptide-1 receptor agonists and ...

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a cardiometabolic syndrome driven by obesity and related metabolic risk factors, yet strategies to prevent progression to clinically overt heart failure in at-risk populations remain limited. We evaluated the association between initiation of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy and ...
Key Details About Glucagon Like Peptide 1 Receptor Agonists And Heart Failure

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), established treatments for type 2 diabetes and obesity, exhibit cardiovascular benefits extending to heart failure (HF) with preserved ejection fraction (HFpEF). Mechanisms contributing to HF improvement include significant weight loss, blood pressure reduction, enhanced glycaemic control, anti-inflammatory effects and potential direct ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for glycaemic control in patients with type 2 diabetes, have demonstrated significant cardiometabolic benefits beyond glucose regulation. These agents have multiple effects, including reducing body weight, improving insulin sensitivity, anti-inflammatory properties and enhancing endothelial function. All these ...

Useful Notes on Glucagon Like Peptide 1 Receptor Agonists And Heart Failure
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiovascular outcomes in obesity and heart failure and preserved ejection fraction; however, their safety and efficacy in heart failure with reduced ejection fraction (HFrEF) remain uncertain. We sought to evaluate the efficacy and safety of GLP-1RAs in patients with HFrEF.
Heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF) is often associated with obesity and metabolic dysfunction. Recent data suggest that incretin-based therapies, including glucagon-like peptide-1 receptor ...

Overview of Glucagon Like Peptide 1 Receptor Agonists And Heart Failure
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular (CV) benefits, but their effects across the heart failure (HF) spectrum remain uncertain. We synthesized randomized evidence comparing GLP-1 RAs with placebo in adults with HF across ejection fraction phenotypes by searc …
Heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF) is often associated with obesity and metabolic dysfunction. Recent data suggest that incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide improve cardiovascular outcomes in patients with HFpEF or HFmrEF both with and without diabetes. However, whether the ...

Key Details About Glucagon Like Peptide 1 Receptor Agonists And Heart Failure
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown improved symptomatic relieving and functional capacity in patients with heart failure (HF) with preserved ejection fraction and obesity.






Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure : STEPping Across the Ejection Fraction Divide∗ Original Investigation: Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction Authors: Muthiah Vaduganathan mvaduganathan@bwh.harvard.edu and John W. Ostrominski Authors Info ...